{"id":"placebo-for-relugolix","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL1800159","moleculeType":"Small molecule","molecularWeight":"623.64"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebos are inert formulations used in randomized controlled trials to provide a baseline against which the active drug's effects can be measured. In Phase 3 trials for relugolix, the placebo arm allows researchers to distinguish genuine therapeutic effects from natural disease progression or placebo response. This is a standard control rather than a therapeutic agent.","oneSentence":"A placebo control contains no active pharmaceutical ingredient and serves as a comparator in clinical trials to establish the efficacy of relugolix.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:25.833Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT06671548","phase":"PHASE3","title":"Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2024-01-15","conditions":"Heavy Menstrual Bleeding, Uterine Fibroids","enrollment":120},{"nctId":"NCT05053152","phase":"PHASE2","title":"Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2022-04-20","conditions":"Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Ductal Adenocarcinoma","enrollment":194},{"nctId":"NCT03751124","phase":"PHASE3","title":"Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2018-10-16","conditions":"Uterine Leiomyoma, Uterine Fibroids","enrollment":229},{"nctId":"NCT03103087","phase":"PHASE3","title":"LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2017-06-14","conditions":"Heavy Menstrual Bleeding, Uterine Fibroid","enrollment":382},{"nctId":"NCT03049735","phase":"PHASE3","title":"LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2017-04-26","conditions":"Heavy Menstrual Bleeding, Uterine Fibroid","enrollment":388},{"nctId":"NCT03204331","phase":"PHASE3","title":"SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2017-11-01","conditions":"Endometriosis Related Pain","enrollment":623},{"nctId":"NCT03204318","phase":"PHASE3","title":"SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2017-12-07","conditions":"Endometriosis Related Pain","enrollment":638},{"nctId":"NCT02655237","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-03-05","conditions":"Uterine Fibroids","enrollment":281},{"nctId":"NCT02655224","phase":"PHASE3","title":"A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-03-26","conditions":"Uterine Fibroids","enrollment":65},{"nctId":"NCT01452685","phase":"PHASE2","title":"A Long-term Extension Study of TAK-385 in the Treatment of Endometriosis","status":"COMPLETED","sponsor":"Takeda","startDate":"2012-03","conditions":"Endometriosis","enrollment":397},{"nctId":"NCT01458301","phase":"PHASE2","title":"Efficacy and Safety of TAK-385 in the Treatment of Endometriosis","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-10","conditions":"Endometriosis","enrollment":487},{"nctId":"NCT01452659","phase":"PHASE2","title":"Efficacy and Safety of TAK-385 in the Treatment of Uterine Fibroids","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-10","conditions":"Uterine Fibroids","enrollment":216}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":35,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo for relugolix","genericName":"Placebo for relugolix","companyName":"Myovant Sciences GmbH","companyId":"myovant-sciences-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Relugolix is a small molecule gonadotropin-releasing hormone receptor antagonist used in clinical trials for conditions such as heavy menstrual bleeding, uterine fibroids, and oligometastatic prostate carcinoma. In a Phase 3 clinical trial (NCT06671548), a placebo of relugolix was used as a control in a study comparing its efficacy and safety to estradiol/norethindrone acetate in women with heavy menstrual bleeding associated with uterine fibroids.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}